Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell-Mediated Killing

详细信息    查看全文

• 作者：Sofia R. Gameiro ; PhD^&lowast ; ; Anthony S. Malamas ; PhD^&lowast ; ; Michael B. Bernstein ; MD^&dagger ; ; Kwong Y. Tsang ; PhD^&lowast ; ; April Vassantachart ; BS^&dagger ; ; Narayan Sahoo ; PhD^&dagger ; ; Ramesh Tailor ; PhD^&dagger ; ; Rajesh Pidikiti ; PhD^&dagger ; ; Chandan P. Guha ; MBBS ; BS ; PhD^&Dagger ; ; Stephen M. Hahn ; MD^&dagger ; ; Sunil Krishnan ; MD^&dagger ; ; James W. Hodge ; PhD ; MBA^&lowast ; ; ^{jh241d@nih.gov" class="auth_mail" title="E-mail the corresponding author}
• 刊名：International Journal of Radiation Oncology*Biology*Physics
• 出版年：2016
• 出版时间：1 May 2016
• 年：2016
• 卷：95
• 期：1
• 页码：120-130
• 全文大小：4684 K

文摘

To provide the foundation for combining immunotherapy to induce tumor antigen–specific T cells with proton radiation therapy to exploit the activity of those T cells.

Methods and Materials

15">Using cell lines of tumors frequently treated with proton radiation, such as prostate, breast, lung, and chordoma, we examined the effect of proton radiation on the viability and induction of immunogenic modulation in tumor cells by flow cytometric and immunofluorescent analysis of surface phenotype and the functional immune consequences.

Results

These studies show for the first time that (1) proton and photon radiation induced comparable up-regulation of surface molecules involved in immune recognition (histocompatibility leukocyte antigen, intercellular adhesion molecule 1, and the tumor-associated antigens carcinoembryonic antigen and mucin 1); (2) proton radiation mediated calreticulin cell-surface expression, increasing sensitivity to cytotoxic T-lymphocyte killing of tumor cells; and (3) cancer stem cells, which are resistant to the direct cytolytic activity of proton radiation, nonetheless up-regulated calreticulin after radiation in a manner similar to non-cancer stem cells.

Conclusions

These findings offer a rationale for the use of proton radiation in combination with immunotherapy, including for patients who have failed radiation therapy alone or have limited treatment options.